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Summary The pNR-2/pS2 protein is regulated by oestrogens in breast cancer cell lines. This report describes
a systematic survey of pNR-2/pS2 expression in a number of common epithelial tumours. Expression was
evaluated immunohistochemically in an archival series using antisera raised against the C-terminus of the
pNR-2/pS2 protein. Expression of pNR-2/pS2 by malignant epithelial tumours was widespread. Intense
immunohistochemical staining was found in tumour cells in a proportion of pancreatic (6/8), large intestinal
(7/12), gastric (9/16) and endometrial (4/12) carcinomas. Positive staining for the pNR-2/pS2 protein was also
found in both benign and malignant ovarian epithelial tumours and was very significantly associated with
mucinous differentiation (P <0.00001). Small numbers of carcinomas of bladder (2/10) and prostate (2/7)
showed less intense staining and single examples ofcervical carcinoma (1/7) and lung carcinoma (1/19) stained
positively. None of the renal carcinomas (0/16) examined stained positively. Positive staining showed no
correlation with gender. Although there are reports of oestrogen receptor expression in most of the tumour
types considered, the possibility of other regulatory influences must also be considered. The pNR-2/pS2
protein may well have a more general role in human epithelial neoplasia than hitherto realised.
The pNR-2/pS2 messenger RNA was originally detected in
oestrogen-responsive breast cancer cell lines by virtue of its
regulation by oestrogen (Masiakowski et al., 1982;
Prud'homme et al., 1985; May & Westley, 1986). The pNR-
2/pS2 mRNA encodes a small, cysteine-rich protein of 84
amino acids (Jakowlew et al., 1984) which is secreted from
breast cancer cells (Nunez et al., 1987) as a mature 60 amino
acid protein (Rio et al., 1988a). Oestrogen regulation of the
pNR-2/pS2 gene is conferred by a short enhancer region in
the 5' flanking region of the gene (Berry et al., 1989). The
function of the pNR-2/pS2 protein is unknown but it. shows
some structural similarity to small peptide growth factors
such as insulin-like growth factor I and a high degree of
homology to porcine pancreatic spasmolytic polypeptide (Rio
et al., 1988b). In breast cancer the pNR-2/pS2 mRNA and
protein are expressed predominantly in oestrogen receptor
positive tumours (Rio et al., 1987; Henry et al., 1990; Henry
et al., 1991) and high levels of the protein are predictive of
favourable prognosis (Foekens et al., 1990). Expression of
pNR-2/pS2 is also predictive of a favourable response to
endocrine therapy in advanced breast cancer (Henry et al.,
1991).
In normal tissue, the pNR-2/pS2 protein is expressed in
gastric mucosa (Rio et al., 1988a), small intestinal mucosa
and in normal breast epithelium (Piggott et al., 1991).
Amongst malignant epithelial tumours, the pNR-2/pS2 pro-
tein has been detected in gastric carcinomas (Luqmani et al.,
1989) and gynaecological cancers (Wysocki et al., 1990).
To date there has been no systematic evaluation of the
expression of this intriguing protein in primary epithelial
tumours arising in different organs. We have recently raised a
rabbit polyclonal antiserum to a synthetic peptide derived
from the C-terminal region of the pNR-2/pS2 protein (Pig-
gott et al., 1991). This antiserum is effective on conven-
tionally fixed, paraffin embedded, histological material. We
now report an immunohistochemical survey of pNR-2/pS2
expression in common epithelial tumours.
Materials and methods
Surgically resected tumours and tumour biopsies were fixed
overnight in phosphate-buffered 4% formalin and representa-
tive blocks selected: the majority of blocks were post-fixed in
formal sublimate (saturated aqueous mercuric chloride and
40% formaldehyde, 9: 1). Fixed blocks were dehydrated
through increasing concentrations of ethanol and then
soaked in xylene prior to embedding in paraffin wax. Three
,sm sections were cut onto poly-l-lysine coated slides for
immunohistochemical study.
In the first instance, sections were stained immunohisto-
chemically using a diaminobenzidine peroxidase: antiperoxi-
dase technique (Sternberger et al., 1970) as described
previously (Piggott et al., 1991). The primary-antiserum was
a rabbit polyclonal raised against a synthetic 31 amino acid
peptide corresponding to the C-terminus of the pNR-2/pS2
protein (Piggott et al., 1991). Sections were treated with 0.1%
trypsin prior to application of the primary antiserum (diluted
1/200 in normal swine serum (NSS)). Negative controls were
performed for each case and comprised omission of either the
primary antiserum or of both the primary and the secondary
antisera. Sections of normal gastric body mucosa served as a
positive control for each run of immunohistochemical stain-
ing.
A streptavidin:biotin peroxidase immunohistochemical
technique (Wood & Warnke, 1981) was used to confirm
staining in cases where the peroxidase:antiperoxidase tech-
nique produced equivocal results. In these instances, first the
primary antiserum was applied (diluted 1/200 in NSS), fol-
lowed by biotinylated swine anti-rabbit IgG (Dakopatts;
diluted 1/1000 in NSS), then the steptavidin/biotin/
peroxidase complex was applied (Dakopatts; one part strep-
tavidin to one part biotinylated horseradish peroxidase,
diluted in 100 parts NSS) and immunohistochemical staining
was visualised with diaminobenzidine.
The specificity of the immunohistochemical staining was
confirmed in a proportion of positive tumours by preabsorp-
tion of the primary antiserum. The antiserum was incubated
for 1 h at 37C and then overnight at 4°C in the presence of
the synthetic peptide immunogen (0.625 mg ml') prior to
the standard immunohistochemical procedure.
In positively stained tumours, an estimate of the propor-
tion of stained tumour cells was made by counting the
number of positively and negatively stained tumour cells in
four randomly selected, medium power microscope fields
(usually approximately 1,000 tumour cells in total).
Results
All tumours that contained positively stained cells were con-
sidered positive, regardless of the proportion of cells staining.
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The specific detection of pNR-2/pS2 expression was confirmed
by the absence of staining when the antisera was preabsorbed
with the synthetic peptide that had been used as the immuno-
gen. There was considerable variation in the proportion of
tumour cells that expressed pNR-2/pS2 and in the intensity
of staining.
The highest incidence of positive staining was found in
pancreatic carcinomas (75%; Table I). Positive pNR-2/pS2
immunohistochemical staining was cytoplasmic and showed a
tendency to perinuclear accentuation (Figure 1). Pancreatic
tumours also contained some of most intensely stained cells
and some of them contained high proportions of positively
stained cells (Table I). Positive cytoplasmic staining was found
in tumour cells scattered throughout the neoplastic glandular
elements: background staining was minimal (Figure 1).
Intense cytoplasmic staining of tumour cells was also
found in appreciable numbers of carcinomas of large bowel
(58%), stomach (56%) and endometrium (33%; Table I). In
all of the positive examples, tumour cell staining was again
cytoplasmic with a tendency to perinuclear accentuation. In
positively stained large bowel carcinomas both diffuse and
focal patterns of staining were observed (Figure 2). In
general, if large proportions of tumour cells stained,
positively stained cells were present scattered diffusely
throughout the tumour whereas staining tended to be more
focal in large bowel carcinomas containing smaller propor-
tions ofpositive cells. Focal positive staining was also present
in apparently normal large bowel epithelium adjacent to one
tumour. Both diffuse and focal patterns of staining were
observed in positively stained gastric carcinomas. Positive
staining was observed in tumours exhibiting both glandular
and diffuse histological patterns (Figure 3a,b). Epithelial cells
in adjacent uninvolved gastric mucosa showed the pattern of
staining previously observed in normal gastric mucosa (Pig-
gott et al., 1991). In all four positively stained endometrial
carcinomas, the positive tumour cells were present scattered
widely throughout the tumour: this included one tumour
where only approximately 1% of tumour cells stained
positively. Positive staining was confined to malignant
epithelial cells; the stromal component only demonstrated
weak background staining (Figure 4).
Ovarian tumours formed a particularly interesting group.
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Figure 1 Positive immunohistochemical staining for pNR-2/pS2
in a proportion of cells in a pancreatic adenocarcinoma. Staining
is cytoplasmic with a tendency to perinuclear accentuation
(arrow). Bar = 501tm.
Figure 2 A colorectal carcinoma with positive pNR-2/pS2
immunohistochemical staining of varying intensity in a propor-
tion of tumour cells lining glandular structures (arrow).
Bar = 50gm.
Table I pNR-2/pS2 immunohistochemical staining in primary cancers of different sites
Positive tumours,
No. pNR-2/pS2 Proportion of Proportion of mean proportion
Total no. positive cases male pNR-2/pS2 female pNR-2/pS2 positively-stained
Primary site cases (%) positive cases (%) positive cases (%) cells (%) Range
Pancreas 8 6 (75%) 2/3 (67%) 4/5 (80%) 42% 7-57%
Large bowel 12 7 (58%) 5/8 (63%) 2/4 (50%) 20% 4-60%
Stomach 16 9 (56%) 4/7 (57%) 5/9 (55%) 27% 0.5-77%
Ovary 25 9 (36%) 9/25 (36%) 21% 1-61%
Endometrium 12 4 (33%) 4/12 (33%) 26% 1-56%
Prostate 7 2 (29%) 2/7 (29%) 2.5% 2-3%
Bladder 10 2 (20%) 2/7 (29%) 0/3 (0%) 30% 7-53%
Cervix 7 1 (14%) 1/7 (14%) 1%
Lung 19 1 (5%) 0/14 (0%) 1/5 (20%) 62%
Kidney 16 0 0/5 (0%) 0/11 (0%) 0% -
Breast 171 117 (67%) 117/171 (67%) 14.9% 1 -81%PNR-2/PS2 EXPRESSION IN DIVERSE HUMAN CARCINOMAS
a, ff
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Figure 4 Positive pNR-2/pS2 immunohistochemical staining in a
primary endometrial carcinoma: staining is cytoplasmic with
perinuclear accentuation (arrow) and there is minimal stromal
staining. Bar = 50ftm.
ovarian tumours showed that there was a significant associa-
tion between pNR-2/pS2 positivity and mucinous subtype
(Table II; Fisher's exact probability = 0.0083). A group of
benign serous and mucinous cystadenomas were stained
immunohistochemically to investigate whether mucinous
differentiation was associated with pNR-2/pS2 expression in
benign tumours. In these benign tumours, positive staining
was confined to epithelial cells lining cystic spaces and
although more prevalent was often less intense than that
observed in their malignant counterparts (Figure Sb). In
general, positively stained cells were found scattered around
the circumference of the cystic spaces in these benign
tumours, but in some instances the pattern was more focal.
The association between positive pNR-2/pS2 immunohisto-
chemical staining and mucinous differentiation was significant
in the group of benign tumours (Table II; Fisher's exact
probability = 0.001). The association between pNR-2/pS2
expression and mucinous differentiation became even more
highly significant when the groups of benign and malignant
ovarian tumours were combined (Fisher's exact probability
<0.00001).
Strong positive immunohistochemical staining was present
in a large proportion of cells present diffusely throughout a
single adenocarcinoma of lung. The remaining lung cancers
(comprising eight adenocarcinomas and ten undifferentiated
large cell carcinomas) did not appear to express pNR-2/pS2
(Table I).
Less intense immunohistochemical staining for pNR-2/pS2
was present in cells scattered throughout two transitional cell
carcinomas of bladder and in small foci of cells present in
two prostatic adenocarcinomas. A single cervical carcinoma
contained a small focus of positively stained tumour cells.
This was the only adenocarcinoma analysed in a group which
otherwise comprised squamous carcinomas of cervix. None
of the 16 renal adenocarcinomas examined showed any
evidence of pNR-2/pS2 expression (Table I).
Figure 3 a, Scattered tumour cells showing positive pNR-2/pS2
immunohistochemical staining in a primary gastric carcinoma of
glandular type (arrow). Bar = 50gm. b, Positive pNR-2/pS2
immunohistochemical staining in a primary gastric carcinoma of
diffuse type. The cytoplasm of tumour cells is intensely stained
(large arrow) while only low levels of staining are present in the
cytoplasm of the gastric glands (small arrow). Bar = 50;Lm.
In total 25 malignant tumours were stained, comprising 14
serous cystadenocarcinomas, eight mucinous cystadenocar-
cinomas and three unclassifiable, poorly differentiated car-
cinomas. In the nine positively stained tumours, strongly
stained tumour cells were typically present scattered diffusely
throughout the tumour, with only minimal stromal staining
(Figure 5a). Further analysis of the pattern of staining in the
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Figure 5 a, pNR-2/pS2 immunohistochemical staining in a pro-
portion of tumour cells in a mucinous cystadenocarcinoma of
ovary. The intensity of tumour cell staining varies. There is
minimal background stromal staining. Bar = 50 jm. b, A benign
mucinous cystadenoma of ovary. There is intense immunohisto-
chemical staining for pNR-2/pS2 in a proportion of cells (arrow)
and a lower level of staining in the majority of the rest of the
epithelium. Bar = 50 ym.
Discussion
The pNR-2/pS2 protein was discovered in human breast
cancer cells (Masiakowski et al., 1982; Prud'homme et al.,
1985; May & Westley, 1986; Skilton et al., 1989) but its
expression has since been reported in gastric (Luqmani et al.,
1989) and gynaecological cancers (Wysocki et al., 1990). This
report is the first survey of the extent of the pNR-2/pS2
expression in common human epithelial tumours. We have
found that pNR-2/pS2 expression is a widespread
phenomenon: of the tumours examined only renal adenocar-
cinomas did not show any expression at all (TableI). Con-
vincing pNR-2/pS2 immunohistochemical staining was found
in appreciable numbers of carcinomas of pancreas, large
bowel, stomach, ovary and endometrium: weaker staining
was found in a proportion of prostatic and bladder car-
cinomas. Single examples of both cervical and lung car-
cinomas stained positively. We detected a lower proportion
of pNR-2/pS2 positive gastric carcinomas than Luqmani et
al. (1989) but as both studies included only relatively small
numbers of gastric carcinomas the proportions may be con-
sidered broadly comparable. The proportion of ovarian and
endometrial carcinomas in which pNR-2/pS2 was detectable
immunohistochemically is however considerably higher than
that reported by Wysocki et al. (1990) who studied expression
of pNR-2/pS2 mRNA in Northern blots of total cellular
RNA extracts: it is possible that the significant proportion of
stromal cells in these tumours militates against detection of a
mRNA expressed solely in a proportion of the malignant
epithelial cells.
For the purposes of comparison, the results obtained with
a large series (171) of primary breast tumours (Henry et al.,
1991) are shown in Table I. While the numbers of tumours in
each group in the present series are smaller, it is interesting
that pNR-2/pS2 is expressed in a similar proportion of
breast, pancreatic, large bowel and gastric tumours. In addi-
tion, the mean proportion of cells in which pNR-2/pS2 ex-
pression was detected in the breast tumours is lower than in
some of the other tumour types. Thus pNR-2/pS2 expression
is at least as prevalent in some other epithelial tumours as it
is in breast cancer.
Malignant ovarian tumours of surface epithelium form a
heterogeneous group and the current series was chosen to
represent the more common tumours which show either
serous or mucinous differentiation. Immunohistochemical
staining for the pNR-2/pS2 protein was found to associate
very significantly with mucinous diffentiation (Table II): a
similar association with mucinous differentiation has been
observed by Wysocki et al. (1990) but they did not have
sufficient numbers of pNR-2/pS2 positive tumours for statis-
tical analysis. We have investigated this association further in
a series of benign serous and mucinous cystadenomas of
ovary and found a similar and significant association.
Although the association of pNR-2/pS2 expression with
mucinous differentition is not absolute, antibodies to pNR-2/
pS2 may be useful reagents for determining differentiation in
diagnostically problematic ovarian tumours. The divergent
differentiation found in ovarian epithelial tumours is thought
to result from the capacity of ovarian surface epithelium to
differentiate into each of the types of Mullerian epithelium,
with mucinous tumours differentiating along the line of
endocervical epithelium. A series of normal endocervices in
ten hysterectomy specimens was also stained immunohisto-
chemically with the pNR-2/pS2 antiserum but there was no
evidence of pNR-2/pS2 expression (data not shown). It is
however interesting that the only cervical carcinoma to stain
positively was the only adenocarcinoma of endocervix in a
group otherwise composed to squamous carcinomas. Expres-
sion of pNR-2/pS2 in epithelial tumours of Mullerian origin
may occur as part of neoplastic progression.
We have detected pNR-2/pS2 expression in normal breast,
stomach, small intestine and prostate in a previous study
(Piggott et al., 1991) and in apparently normal large bowel
epithelium adjacent to a colonic tumour in the present study.
Wright et al. (1991) have described pNR-2/pS2 expression in
intestinal mucosa adjacent to areas of mucosal damage and it
is possible that a similar phenomenon occurs in normal
colorectal epithelium adjacent to some tumours. Clearly
pNR-2/pS2 expression by human malignant epithelial
tumours is not restricted to those tissues in which the proteinPNR-2/PS2 EXPRESSION IN DIVERSE HUMAN CARCINOMAS 681
Table II pNR-2 immunohistochemical staining in benign and malignant primary ovarian
tumours
Positive tumours,
No. pNR-2/pS2 mean proportion
Total no. positive cases positively-stained
Tumour type cases (%) cells (%) Range
Serouscystadenocarcinoma 14 2 (14%) 3% 1-5%
Mucinous cystadenocarcinoma 8 6(75%) 20% 14-29%
Serouscystadenoma 14 5 (36%) 18% 15-24%
Mucinouscystadenoma 11 11(100%) 37% 10-71%
is normally expressed. The factors that control the ectopic
expression of this protein are currently unknown.
In human breast cancer at least, expression of the pNR-2/
pS2 mRNA or protein is almost entirely confined to a pro-
portion of breast cancers that express oestrogen receptor
(Rio et al., 1987; Skilton et al., 1989; Henry et al., 1990;
Foekens et al., 1990). This implies that oestrogens regulate
the expression of the pNR-2/pS2 gene in breast cancer cells.
The question then arises, is this gene regulated by oestrogens
acting through the oestrogen receptor in the other malignant
tumours in which it is expressed? Oestrogen receptor has
been detected in a proportion of ovarian epithelial tumours
(Schwartz et al., 1982; Bizzi et al., 1988) and endometrial
carcinomas (Palmer et al., 1988). More surprisingly, oestro-
gen receptor has also been detected in gastric carcinomas
(Sica et al., 1984; Tokunga et al., 1986), colorectal car-
cinomas (McClendon et al., 1977; Sica et al., 1984) and
pancreatic carcinomas (Greenway et al., 1981). Furthermore,
a favourable response to antioestrogen therapy and other
endocrine therapies has been recorded in pancreatic car-
cinoma (reviewed by Greenway, 1987). Expression ofpNR-2/
pS2 in normal gastric mucosa and gastric carcinomas has
however been reported to be independent of oestrogen recep-
tor expression (Rio et al., 1988a; Luqmani et al., 1989) and
Wysocki et al. (1990) only observed a weak correlation
between oestrogen receptor mRNA and pNR-2/pS2 mRNA
expression in ovarian epithelial tumours. Unfortunately, as
the tumours in this study are an archival series from which
only formalin fixed, paraffin embedded material is available
and as receptor assays were not performed at the time of
resection we are unable to correlate oestrogen receptor and
pNR-2/pS2 expression. However in the current series, gender
(and consequent gender dependent differences in sex steroid
levels) did not show any relationship to the proportion of
tumours expressing pNR-2/pS2 (Table I). As the majority of
tumours from women were from elderly, postmenopausal
women analysis of the effect of menopausal status was not
possible.
Other factors may regulate pNR-2/pS2 gene expression in
these tumours. The pNR-2/pS2 gene has a complex upstream
promoter region that contains enhancer elements responsive
to epidermal growth factor, the c-Ha-ras oncoprotein, the
c-jun protein and a tumour promoter (Nunez et al., 1989).
Co-expression of epidermal growth factor and pNR-2/pS2
has been described in intact mucosa at the edge of intestinal
ulcers and it has been suggested that in this instance pNR-2/
pS2 expression is controlled by epidermal growth factor
(Wright et al., 1991). It is also possible that pNR-2/pS2 is
expressed constitutively in a proportion of tumours.
The function of the pNR-2/pS2 protein however remains
enigmatic. If the pNR-2/pS2 protein is indeed a growth
factor it is possible that it may stimulate tumour growth by
autocrine means. The biological and prognostic significance
of pNR-2/pS2 expression, particularly in non-mammary
tumours, remains to be determined. The frequent expression
of this protein in diverse human malignancies suggests that
pNR-2/pS2 could have a more general role in human neo-
plasia than hitherto realised.
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